Bora Biologics Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
CDMO Contract Process Development and Manufacturing Services
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90552221
Status
Closed
Number of Employees
0
Total Paid-in
Capital
- (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Bora Biologics Co., Ltd. is a subsidiary of Bora Pharmaceuticals, Taiwan's largest pharmaceutical group, focusing on the contract manufacturing of macromolecular drugs. Formerly known as Baofeng Biotech, it was renamed Bora Biologics Co., Ltd. in 2023. In 2025, it merged with Tanvex and was dissolved. Bora Biologics Co., Ltd. established its presence in the Hsinchu Biomedical Park, setting up a global antibody drug R&D center and a pilot plant that complies with cGMP standards. It is one of the few domestic companies with macromolecular biologic drug R&D capabilities and production facilities certified by multiple countries. The core of its biotech R&D and manufacturing team has completed dozens of batches of clinical trial drug production, and the produced protein biologics have been used in Phase I to Phase III human clinical trials in more than a dozen countries, including Taiwan, Europe, the United States, Australia, and China.
The content above was translated by Ai
